148 related articles for article (PubMed ID: 38638445)
1. Phenotypic immune characterization of gastric and esophageal adenocarcinomas reveals profound immune suppression in esophageal tumor locations.
Groen-van Schooten TS; Harrasser M; Seidel J; Bos EN; Fleitas T; van Mourik M; Pouw RE; Goedegebuure RSA; Doeve BH; Sanders J; Bos J; van Berge Henegouwen MI; Thijssen VLJL; van Grieken NCT; van Laarhoven HWM; de Gruijl TD; Derks S
Front Immunol; 2024; 15():1372272. PubMed ID: 38638445
[TBL] [Abstract][Full Text] [Related]
2. Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma.
Salem ME; Puccini A; Xiu J; Raghavan D; Lenz HJ; Korn WM; Shields AF; Philip PA; Marshall JL; Goldberg RM
Oncologist; 2018 Nov; 23(11):1319-1327. PubMed ID: 29866946
[TBL] [Abstract][Full Text] [Related]
3. Prediction of tissue origin of adenocarcinomas in the esophagogastric junction by DNA methylation.
Zhang CD; Takeshima H; Sekine S; Yamashita S; Liu YY; Hattori N; Abe H; Yamashita H; Fukuda M; Imamura Y; Ushiku T; Katai H; Makino H; Watanabe M; Seto Y; Ushijima T
Gastric Cancer; 2022 Mar; 25(2):336-345. PubMed ID: 34557982
[TBL] [Abstract][Full Text] [Related]
4. Genomic similarity between gastroesophageal junction and esophageal Barrett's adenocarcinomas.
Ferrer-Torres D; Nancarrow DJ; Kuick R; Thomas DG; Nadal E; Lin J; Chang AC; Reddy RM; Orringer MB; Taylor JM; Wang TD; Beer DG
Oncotarget; 2016 Aug; 7(34):54867-54882. PubMed ID: 27363029
[TBL] [Abstract][Full Text] [Related]
5. A study of the immune infiltrate and patient outcomes in esophageal cancer.
Conroy MJ; Kennedy SA; Doyle SL; Hayes B; Kavanagh M; van der Stok EP; O'Sullivan K; Cathcart MC; Reynolds JV; Lysaght J
Carcinogenesis; 2021 Apr; 42(3):395-404. PubMed ID: 32940666
[TBL] [Abstract][Full Text] [Related]
6. Tumor-immune landscape patterns before and after chemoradiation in resectable esophageal adenocarcinomas.
Soeratram TT; Creemers A; Meijer SL; de Boer OJ; Vos W; Hooijer GK; van Berge Henegouwen MI; Hulshof MC; Bergman JJ; Lei M; Bijlsma MF; Ylstra B; van Grieken NC; van Laarhoven HW
J Pathol; 2022 Mar; 256(3):282-296. PubMed ID: 34743329
[TBL] [Abstract][Full Text] [Related]
7. Human papillomavirus not detected in esophageal adenocarcinoma tumor specimens.
Antonsson A; Knight L; Whiteman DC;
Cancer Epidemiol; 2016 Apr; 41():96-8. PubMed ID: 26895084
[TBL] [Abstract][Full Text] [Related]
8. Immune microenvironment in Barrett's esophagus adjacent to esophageal adenocarcinoma: possible influence of adjacent mucosa on cancer development and progression.
Gokon Y; Fujishima F; Taniyama Y; Ishida H; Yamagata T; Sawai T; Uzuki M; Ichikawa H; Itakura Y; Takahashi K; Yajima N; Hagiwara M; Nishida A; Ozawa Y; Sakuma T; Kanba R; Sakamoto K; Zuguchi M; Saito M; Kamei T; Sasano H
Virchows Arch; 2020 Dec; 477(6):825-834. PubMed ID: 32533341
[TBL] [Abstract][Full Text] [Related]
9. The tight junction protein claudin 6 is a potential target for patient-individualized treatment in esophageal and gastric adenocarcinoma and is associated with poor prognosis.
Simon AG; Lyu SI; Laible M; Wöll S; Türeci Ö; Şahin U; Alakus H; Fahrig L; Zander T; Buettner R; Bruns CJ; Schroeder W; Gebauer F; Quaas A
J Transl Med; 2023 Aug; 21(1):552. PubMed ID: 37592303
[TBL] [Abstract][Full Text] [Related]
10. Adenocarcinomas of the distal esophagus and "gastric cardia" are predominantly esophageal carcinomas.
Chandrasoma P; Wickramasinghe K; Ma Y; DeMeester T
Am J Surg Pathol; 2007 Apr; 31(4):569-75. PubMed ID: 17414104
[TBL] [Abstract][Full Text] [Related]
11. Analysis of Spatial Organization of Suppressive Myeloid Cells and Effector T Cells in Colorectal Cancer-A Potential Tool for Discovering Prognostic Biomarkers in Clinical Research.
Zwing N; Failmezger H; Ooi CH; Hibar DP; Cañamero M; Gomes B; Gaire F; Korski K
Front Immunol; 2020; 11():550250. PubMed ID: 33193316
[TBL] [Abstract][Full Text] [Related]
12. Distribution of tumor-infiltrating-T-lymphocytes and possible tumor-escape mechanisms avoiding immune cell attack in locally advanced adenocarcinomas of the esophagus.
Schoemmel M; Loeser H; Kraemer M; Wagener-Ryczek S; Hillmer A; Bruns C; Thelen M; Schröder W; Zander T; Lechner A; Buettner R; Schlösser H; Gebauer F; Quaas A;
Clin Transl Oncol; 2021 Aug; 23(8):1601-1610. PubMed ID: 33566304
[TBL] [Abstract][Full Text] [Related]
13. Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry.
Alvarez-Manceñido F; Jimenez-Fonseca P; Carmona-Bayonas A; Arrazubi V; Hernandez R; Cano JM; Custodio A; Pericay Pijaume C; Aguado G; Martínez Lago N; Sánchez Cánovas M; Cacho Lavin D; Visa L; Martinez-Torron A; Arias-Martinez A; López F; Limón ML; Vidal Tocino R; Fernández Montes A; Alsina M; Pimentel P; Reguera P; Martín Carnicero A; Ramchandani A; Granja M; Azkarate A; Martín Richard M; Serra O; Hernández Pérez C; Hurtado A; Gil-Negrete A; Sauri T; Morales Del Burgo P; Gallego J
Gastric Cancer; 2021 Jul; 24(4):926-936. PubMed ID: 33651195
[TBL] [Abstract][Full Text] [Related]
14. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma.
Thompson ED; Zahurak M; Murphy A; Cornish T; Cuka N; Abdelfatah E; Yang S; Duncan M; Ahuja N; Taube JM; Anders RA; Kelly RJ
Gut; 2017 May; 66(5):794-801. PubMed ID: 26801886
[TBL] [Abstract][Full Text] [Related]
15. Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough.
Weinberg BA; Xiu J; Hwang JJ; Shields AF; Salem ME; Marshall JL
Oncologist; 2018 Oct; 23(10):1171-1177. PubMed ID: 29703766
[TBL] [Abstract][Full Text] [Related]
16. Immune determinants of Barrett's progression to esophageal adenocarcinoma.
Lagisetty KH; McEwen DP; Nancarrow DJ; Schiebel JG; Ferrer-Torres D; Ray D; Frankel TL; Lin J; Chang AC; Kresty LA; Beer DG
JCI Insight; 2021 Jan; 6(1):. PubMed ID: 33290281
[TBL] [Abstract][Full Text] [Related]
17. Individualized surgical strategies for cancer of the esophagogastric junction.
Stein HJ; Feith M; Siewert JR
Ann Chir Gynaecol; 2000; 89(3):191-8. PubMed ID: 11079787
[TBL] [Abstract][Full Text] [Related]
18. Deciphering the Immune Complexity in Esophageal Adenocarcinoma and Pre-Cancerous Lesions With Sequential Multiplex Immunohistochemistry and Sparse Subspace Clustering Approach.
Sundaram S; Kim EN; Jones GM; Sivagnanam S; Tripathi M; Miremadi A; Di Pietro M; Coussens LM; Fitzgerald RC; Chang YH; Zhuang L
Front Immunol; 2022; 13():874255. PubMed ID: 35663986
[TBL] [Abstract][Full Text] [Related]
19. The adaptive immune and immune checkpoint landscape of neoadjuvant treated esophageal adenocarcinoma using digital pathology quantitation.
Humphries MP; Craig SG; Kacprzyk R; Fisher NC; Bingham V; McQuaid S; Murray GI; McManus D; Turkington RC; James J; Salto-Tellez M
BMC Cancer; 2020 Jun; 20(1):500. PubMed ID: 32487090
[TBL] [Abstract][Full Text] [Related]
20. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients.
Rüdiger Siewert J; Feith M; Werner M; Stein HJ
Ann Surg; 2000 Sep; 232(3):353-61. PubMed ID: 10973385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]